5AM Venture Management LLC Sells 307,288 Shares of Enliven Therapeutics, Inc. $ELVN

Key Points

• 5AM Venture Management LLC has reduced its position in Enliven Therapeutics by 18.9%, now holding approximately 1.32 million shares of the company's stock.
• Enliven Therapeutics has recently experienced changes in institutional ownership, with other investors like Invesco Ltd. and California State Teachers Retirement System increasing their stakes in the company.
• Despite recent stock sales by insiders, analysts continue to maintain a "Buy" rating on Enliven, with a consensus price target of $41.20.

5AM Venture Management LLC decreased its holdings in Enliven Therapeutics, Inc. (NASDAQ:ELVN - Free Report) by 18.9% during the 1st quarter, according to its most recent disclosure with the SEC. The firm owned 1,322,477 shares of the company's stock after selling 307,288 shares during the period. Enliven Therapeutics makes up about 9.8% of 5AM Venture Management LLC's investment portfolio, making the stock its 2nd largest position. 5AM Venture Management LLC owned 2.70% of Enliven Therapeutics worth $26,026,000 as of its most recent SEC filing.

Several other institutional investors also recently bought and sold shares of ELVN. Invesco Ltd. lifted its position in shares of Enliven Therapeutics by 3.5% during the fourth quarter. Invesco Ltd. now owns 15,072 shares of the company's stock worth $339,000 after purchasing an additional 508 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its stake in Enliven Therapeutics by 3.7% during the fourth quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 20,036 shares of the company's stock valued at $451,000 after buying an additional 718 shares in the last quarter. Tower Research Capital LLC TRC lifted its holdings in Enliven Therapeutics by 230.2% during the 4th quarter. Tower Research Capital LLC TRC now owns 1,598 shares of the company's stock worth $36,000 after buying an additional 1,114 shares during the last quarter. MetLife Investment Management LLC grew its position in shares of Enliven Therapeutics by 6.3% in the 4th quarter. MetLife Investment Management LLC now owns 21,746 shares of the company's stock worth $489,000 after acquiring an additional 1,285 shares in the last quarter. Finally, California State Teachers Retirement System lifted its stake in Enliven Therapeutics by 10.2% during the fourth quarter. California State Teachers Retirement System now owns 20,914 shares of the company's stock worth $471,000 after purchasing an additional 1,940 shares during the last quarter. 95.08% of the stock is currently owned by hedge funds and other institutional investors.

Enliven Therapeutics Price Performance

Shares of NASDAQ ELVN traded up $0.14 during mid-day trading on Friday, reaching $20.15. 432,313 shares of the company traded hands, compared to its average volume of 397,903. Enliven Therapeutics, Inc. has a fifty-two week low of $13.30 and a fifty-two week high of $30.03. The firm has a market cap of $1.19 billion, a PE ratio of -10.08 and a beta of 0.89. The stock has a fifty day simple moving average of $20.39 and a 200-day simple moving average of $19.75.

Enliven Therapeutics (NASDAQ:ELVN - Get Free Report) last announced its earnings results on Wednesday, August 13th. The company reported ($0.49) EPS for the quarter, topping the consensus estimate of ($0.53) by $0.04. As a group, analysts predict that Enliven Therapeutics, Inc. will post -1.95 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of equities research analysts have issued reports on ELVN shares. The Goldman Sachs Group started coverage on Enliven Therapeutics in a research note on Monday, June 16th. They issued a "buy" rating and a $37.00 target price on the stock. Robert W. Baird lifted their price objective on shares of Enliven Therapeutics from $40.00 to $52.00 and gave the company an "outperform" rating in a research report on Monday, June 16th. HC Wainwright boosted their target price on shares of Enliven Therapeutics from $40.00 to $48.00 and gave the company a "buy" rating in a research note on Wednesday, July 2nd. Finally, Jones Trading dropped their price target on shares of Enliven Therapeutics from $36.00 to $27.00 and set a "buy" rating on the stock in a research note on Friday, May 16th. Five research analysts have rated the stock with a Buy rating, According to data from MarketBeat, the company currently has a consensus rating of "Buy" and an average price target of $41.20.

Insider Transactions at Enliven Therapeutics

In related news, insider Joseph P. Lyssikatos sold 7,500 shares of Enliven Therapeutics stock in a transaction dated Thursday, August 21st. The stock was sold at an average price of $20.01, for a total transaction of $150,075.00. Following the transaction, the insider directly owned 940,188 shares of the company's stock, valued at $18,813,161.88. The trade was a 0.79% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Samuel Kintz sold 10,393 shares of the firm's stock in a transaction dated Monday, August 18th. The shares were sold at an average price of $20.02, for a total transaction of $208,067.86. Following the transaction, the chief executive officer owned 929,999 shares of the company's stock, valued at approximately $18,618,579.98. This trade represents a 1.11% decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders have sold 104,234 shares of company stock worth $2,186,231. Corporate insiders own 25.90% of the company's stock.

Enliven Therapeutics Company Profile

Enliven Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company's lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations.